Monument Therapeutics Reports Positive Phase I Results for Novel Cognitive Impairment Associated with Schizophrenia Treatment

Written By Charlotte Kirby
Charlotte Kirby
Previous

Oxford Space Systems deploys S-Band helical antenna for Astro Digital enhancing satellite communication capabilities
Next

Singular Photonics and AMS Technologies to bring advanced SPAD sensors to Europe